Armata Pharmaceuticals Announces AP‑SA02 Phase 3 Progress; CFO Promotion

What Happened

• On July 20, 2026 Armata Pharmaceuticals (ARMP) issued a press release reporting clinical, regulatory, manufacturing and operational progress that the company says supports advancement of AP‑SA02 — its intravenously administered Staphylococcus aureus (S. aureus) multi‑phage product candidate — toward a planned Phase 3 superiority study as an adjunct treatment for complicated bacteremia caused by MSSA or MRSA.
• The release noted a $2.5 million continuation award from the U.S. Department of Defense announced June 23, 2026, bringing total DoD funding under that award to $28.7 million; these additional funds are intended to support readiness and preparation activities for the planned Phase 3 study. Armata said it is in ongoing discussions with DoD about potential further support and is also pursuing other funding pathways.
• The press release also announced the promotion of David House to Chief Financial Officer. The full press release was furnished as Exhibit 99.1 to the Form 8‑K.

Key Details

• Date of disclosure: July 20, 2026 (press release filed on Form 8‑K, Item 7.01).
• DoD funding: $2.5 million awarded June 23, 2026; total to date under the award is $28.7 million.
• Program: AP‑SA02 is an IV multi‑phage candidate targeting complicated bacteremia from MSSA and MRSA; company preparing for a planned Phase 3 superiority study.
• Corporate change: David House promoted to Chief Financial Officer.

Why It Matters

• Progress toward a Phase 3 study is a material clinical development milestone that could advance AP‑SA02 closer to a potential approval path, which investors typically view as de‑risking compared with earlier‑stage programs.
• Additional non‑dilutive DoD funding ($2.5M, $28.7M total to date) helps cover Phase 3 readiness activities but does not guarantee full funding for the trial; Armata is still seeking other funding sources and potential additional DoD support.
• The CFO promotion is a notable leadership change that may affect execution of financing and operational plans as the company moves toward later‑stage clinical work.